Rhino Biotech Limited
Rhino Biotech Limited intends to develop plant and fungi derived nutraceuticals, and preventative and curative biopharmaceuticals. The company was formerly known as Eurasia Energy Limited and changed its name to Rhino Biotech Limited in September 2021. Rhino Biotech Limited was incorporated in 2003 and is based in South Hill, Anguilla.
Rhino Biotech Limited (RBRXF) - Net Assets
Latest net assets as of : $- USD
Based on the latest financial reports, Rhino Biotech Limited (RBRXF) has net assets worth $- USD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | -434.06% |
| 10-Year Change | N/A |
| Growth Volatility | 37.25 |
Rhino Biotech Limited - Net Assets Trend (2013–2020)
This chart illustrates how Rhino Biotech Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rhino Biotech Limited (2013–2020)
The table below shows the annual net assets of Rhino Biotech Limited from 2013 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | $-60.31K | -54.33% |
| 2019-12-31 | $-39.08K | -109.48% |
| 2018-12-31 | $-18.66K | -290.03% |
| 2017-12-31 | $-4.78K | -126.49% |
| 2016-12-31 | $18.05K | -57.47% |
| 2015-12-31 | $42.45K | -41.00% |
| 2014-12-31 | $71.96K | -31.25% |
| 2013-12-31 | $104.67K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rhino Biotech Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16497600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $34.55K | % |
| Other Comprehensive Income | $7.14 Million | % |
| Total Equity | $-60.31K | 100.00% |
Rhino Biotech Limited Competitors by Market Cap
The table below lists competitors of Rhino Biotech Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MERISTEM GROWTH EXCHANGE TRADED FUND
XNSA:MERGROWTH
|
$2.43K |
|
Nozha International Hospital
EGX:NINH
|
$2.43K |
|
Bosera CMSK Industrial Park
SHE:180101
|
$2.43K |
|
Molecular Data Inc.
PINK:MKDTY
|
$2.44K |
|
Softlogic Life Insurance PLC
CM:AAICN0000
|
$2.42K |
|
Namyeung Vivien Corp.
KQ:002070
|
$2.42K |
|
SILVER GRAIL RES
BE:KD7
|
$2.42K |
|
Northern Sphere Mining Corp
PINK:NSMCF
|
$2.42K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rhino Biotech Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from -39,078 to -60,311, a change of -21,233.
- Net loss of 21,233 reduced equity.
- Other factors decreased equity by 0.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.23K | -35.21% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Rhino Biotech Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.00 | $0.00 | x |
| 2014-12-31 | $0.00 | $0.00 | x |
| 2015-12-31 | $0.00 | $0.00 | x |
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rhino Biotech Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-35.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -36.08% | 0.00% | 0.00x | 1.03x | $-48.23K |
| 2014 | -45.45% | 0.00% | 0.00x | 1.05x | $-39.90K |
| 2015 | -69.49% | 0.00% | 0.00x | 1.07x | $-33.75K |
| 2016 | -135.16% | 0.00% | 0.00x | 1.19x | $-26.21K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.36K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.01K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.52K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.20K |
Industry Comparison
This section compares Rhino Biotech Limited's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rhino Biotech Limited (RBRXF) | $- | -36.08% | N/A | $2.43K |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |